01—Abstract
Summary
Summary of the 10-Q filed April 22, 2025. Cited figures are marked; the original filing is the authoritative source.
Danaher's first quarter 2025 results (three months ended March 28, 2025) show a modest top-line softness with pressure on profitability and earnings.
Sales were $5,741 milliona, down 1.0% year over year from $5,796 million. Core sales (excluding acquisitions and currency) were flat: Biotechnology grew 7.0%, while Life Sciences core sales fell 4.0% and Diagnostics fell 1.5%. Currency reduced reported sales by 1.5%, and acquisitions added 0.5%.
Operating profit fell to $1,274 millionb from $1,312 million, with margin declining 40 basis points to 22.2%. Net earnings dropped 12% to $954 million, and diluted EPS fell to $1.32 from $1.45. The decline reflected higher SG&A (32.4% of sales versus 31.2%, driven by productivity-program costs), a $15 million facility impairment, a $90 million investment loss, and higher net interest expense.
Cash generation and capital allocation were notable. Operating cash flow fell 25% to $1.3 billionc, mainly due to lower earnings and working-capital timing. Danaher repurchased about $1.1 billion of stock (roughly 4.5 million shares at an average of about $239), leaving about 12 million shares authorized.
Cash ended the quarter at $2.0 billion, and long-term debt rose to $16.0 billiond. Comprehensive income of $2.56 billion was driven mainly by a $1.4 billion foreign currency translation gain, which is non-cash and reflects the weaker U.S. dollar. Balance sheet goodwill rose to $41.7 billion, largely from currency translation.
Management flagged meaningful forward risk from new U.S. tariffs and retaliatory measures. The company expects several hundred million dollars of incremental tariff costs in 2025, which it intends to largely offset through sourcing changes, surcharges, and productivity actions. It expects end-market demand for the rest of 2025 to be roughly consistent with Q1, and projects a full-year-remaining effective tax rate of about 17%.
02—Key points
Key Highlights
- Revenue declined 1.0% to $5.74 billion; core sales were flat, with Biotechnology up 7.0% and Life Sciences (-4.0%) and Diagnostics (-1.5%) lower, including China volume-based procurement pressure in Diagnostics.
- Operating margin compressed 40 bps to 22.2%, with Biotechnology margin up sharply to 27.4% while Life Sciences (12.0%) and Diagnostics (29.3%) margins declined.
- Diluted EPS fell 9% to $1.32 from $1.45, and net earnings declined 12% to $954 million, pressured by higher SG&A, investment losses of $90 million, and lower interest income.
- Operating cash flow fell 25% to $1.3 billion, while the company returned capital through $1.1 billion of buybacks and $194 million of dividends, leaving cash at $2.0 billion.
- Management expects several hundred million dollars of incremental 2025 tariff costs, aiming to largely offset operating profit impact through supply chain changes, surcharges, and cost actions.
- Comprehensive income of $2.56 billion was boosted by a $1.4 billion non-cash foreign currency translation gain, while total debt increased to $16.5 billion.
- Management expects end-market demand for the rest of 2025 to be relatively consistent with Q1, and projects an effective tax rate of about 17% for the remainder of the year.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, Danaher Corp kept $0.17.
- Revenue$5.74B100.0%
- Cost of revenue−$2.23B38.8%
- Gross profit$3.51B61.2%
- Operating costs−$2.24B39.0%
- Operating income$1.27B22.2%
- Interest, other & tax−$320.0M5.6%
- Net income$954.0M16.6%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed April 22, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $5.74B$5.80B | −0.9% |
| Cost of Revenue | $2.23B$2.31B | −3.4% |
| Gross Profit | $3.51B$3.49B | +0.7% |
| R&D Expenses | $379.00M$368.00M | +3.0% |
| SG&A Expenses | $1.86B$1.81B | +2.8% |
| Operating Income | $1.27B$1.31B | −2.9% |
| Net Income | $954.00M$1.09B | −12.3% |
| EPS (Basic) | $1.33$1.47 | −9.5% |
| EPS (Diluted) | $1.32$1.45 | −9.0% |
| Shares Outstanding (Basic) | 716.30M740.60M | −3.3% |
| Shares Outstanding (Diluted) | 720.80M748.60M | −3.7% |
05—Questions
Frequently Asked Questions
How did Danaher's underlying business perform in Q1 2025?
Core sales were flat year over year. Biotechnology grew 7.0% on stronger bioprocessing consumables demand, offsetting declines in Life Sciences (-4.0%), driven by genomics consumables at large customers, and Diagnostics (-1.5%), driven by China volume-based procurement and reimbursement changes. Reported sales fell 1.0% because currency reduced sales by 1.5%, partly offset by a 0.5% acquisition contribution.
Why did earnings decline more than sales?
Operating expenses grew faster than sales. SG&A rose to 32.4% of sales from 31.2%, driven by productivity-program costs and acquisition-related amortization. Q1 also included a $15 million facility impairment and $90 million of investment losses. Net interest income fell $54 million on lower cash balances after buybacks, and the effective tax rate rose to 15.5% from 14.4%.
What are the main tariff risks to Danaher's outlook?
Danaher expects incremental 2025 tariff costs of several hundred million dollars under currently enacted tariffs. It plans to largely offset the operating profit impact, but says that if it cannot offset costs or tariffs weaken demand, revenue and profitability would suffer. Additional tariffs, or the delayed tariffs taking effect, could add material costs. The company also notes that U.S.-China tariffs remain significant.
Is Danaher's balance sheet and cash flow still strong enough to support shareholder returns?
Yes, though with less cushion. Cash of $2.0 billion and an undrawn $5.0 billion revolving credit facility support liquidity, and management says it has sufficient sources to meet cash needs. However, total debt rose to $16.5 billion, operating cash flow fell 25%, and Q1 buybacks of about $1.1 billion plus $194 million in dividends exceeded the quarter's free cash flow of roughly $1.05 billion. About 12 million shares remain authorized under the repurchase program.
06—Continue